The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

City of Hope validates Curate Cell Processing System for CAR T-cell therapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

City of Hope has evaluated Curate Biosciences’ Cell Processing System for advanced cell separation and plans to integrate the platform into its workflow to manufacture investigational CAR T-cell immunotherapy, the company said.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Conversation with The Cancer Letter

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
By Matthew Bin Han Ong
In Brief

City of Hope, Charles R. Drew University of Medicine and Science launch new educational research and training program

City of Hope and Charles R. Drew University of Medicine and Science, the only Historically Black Graduate Institution west of the Mississippi River and one of only four Historically Black Medical Schools, announced the launch of a new partnership to educate a more diverse workforce in specialized medicine through internships, curriculum, training, mentorships, joint research projects, and more.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account